References
- Jeon D, Shin D, Kang H, Sung N, Kweon K, Shin E, et al. Trend of multidrug and extensively drug resistant tuberculosis in a tuberculosis referral hospital, 2001- 2005. Tuberc Respir Dis 2008;64:187-193. https://doi.org/10.4046/trd.2008.64.3.187
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2008.
- Caminero JA; World Health Organization; American Thoracic Society; British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006;10:829-837.
- Korea Center for Disease Control and Prevention, Korean Institute of Tuberculosis. Annual report on the notified tuberculosis patients in Korea. Seoul: Korea Center for Disease Control and Prevention; 2005.
- Koh WJ, Kwon OJ, Kim CH, Ahn YM, Lim SY, Yun JW, et al. Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis at a private general hospital. Tuberc Respir Dis 2003;55:154-164.
- Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-1082. https://doi.org/10.1164/rccm.200801-132OC
- World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006;81:430-432.
- Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-645.
- Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R, Facchini A, Guenther G, et al. MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur Respir J 2009;34:778-779. https://doi.org/10.1183/09031936.00059409
- Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002;6:143-149.
- Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrugresistant tuberculosis. J Thorac Cardiovasc Surg 2004; 128:523-528. https://doi.org/10.1016/j.jtcvs.2004.06.012
- Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment treatment outcomes in non-HIV-infected patients with multidrug- resistant tuberculosis. Clin Infect Dis 2007;45: 1290-1295. https://doi.org/10.1086/522537
- Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. https://doi.org/10.1086/590005
- Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem 2008;15:1956-1967. https://doi.org/10.2174/092986708785132906
- Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC 207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-2405. https://doi.org/10.1056/NEJMoa0808427
- Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64:388-391. https://doi.org/10.1093/jac/dkp171
- Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-704. https://doi.org/10.1093/jac/dkl298
Cited by
- The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review vol.16, pp.None, 2010, https://doi.org/10.1186/s12879-016-1524-0